Building IP: AMRN Patent Application re "METHODS OF TREATING MIXED DYSLIPIDEMIA" (1 of 2) | AMRN Message Board Posts

Amarin Corporation plc

  AMRN website

AMRN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  8341 of 8383  at  4/8/2021 1:01:47 AM  by

JBWIN


Building IP: AMRN Patent Application re "METHODS OF TREATING MIXED DYSLIPIDEMIA" (1 of 2)

 
United States Patent Application20210100764
Kind CodeA1
Osterloh; Ian ; et al.April 8, 2021

METHODS OF TREATING MIXED DYSLIPIDEMIA

Abstract

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.


Inventors:Osterloh; Ian; (Kent, GB) ; Wicker; Pierre; (Mystic, CT) ; Braeckman; Rene; (Richboro, PA) ; Soni; Paresh; (Mystic, CT) ; Manku; Mehar; (Birmingham, GB)
Applicant:
NameCityStateCountryType

Amarin Pharmaceuticals Ireland Limited

Dublin

IE
Family ID:1000005290267
Appl. No.:17/127354
Filed:December 18, 2020

Related U.S. Patent Documents

Application NumberFiling DatePatent Number
17027069Sep 21, 2020
17127354
16709492Dec 10, 2019
17027069
16179763Nov 2, 2018
16709492
15273430Sep 22, 201610220013
16179763
14704329May 5, 20159855237
15273430
14175602Feb 7, 20149056088
14704329
13898447May 20, 20138691871
14175602
13540319Jul 2, 20128618166
13898447
13417899Mar 12, 20128563608
13540319
13266085Jan 30, 2012
PCT/US10/32948Apr 29, 2010
13417899
61173759Apr 29, 2009

Current U.S. Class:1/1
Current CPC Class:A61K 45/06 20130101; A61P 3/06 20180101; A61K 31/232 20130101; A61K 31/505 20130101; A61K 47/26 20130101; A61K 31/40 20130101; A61K 31/74 20130101; A61K 31/202 20130101; A61K 47/34 20130101; A61K 31/222 20130101; A61K 47/22 20130101; A61K 9/48 20130101
International Class:A61K 31/202 20060101 A61K031/202; A61K 31/40 20060101 A61K031/40; A61K 45/06 20060101 A61K045/06; A61K 47/22 20060101 A61K047/22; A61K 31/222 20060101 A61K031/222; A61K 9/48 20060101 A61K009/48; A61K 47/26 20060101 A61K047/26; A61K 31/505 20060101 A61K031/505; A61K 31/232 20060101 A61K031/232; A61K 47/34 20060101 A61K047/34

Claims



1. A method of reducing triglycerides in a subject with atrial fibrillation and triglyceride levels of greater than 500 mg/dl, said method comprising administering to said subject an effective amount of icosapent ethyl for a period of time effective to reduce triglyceride levels, whereby said administration also reduces risk of stroke in said subject.

2. The method of claim 1, wherein the subject is on statin therapy.

3. The method of claim 1, wherein the subject has a baseline LDL-C level of about 40 mg/dL to about 100 mg/dL.

4. The method of claim 1, wherein the ethyl icosapentate is present in a pharmaceutical composition and the ethyl icosapentate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition.

5. The method of claim 4, wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules.

6. The method of claim 1, wherein the subject is administered the icosapent ethyl for a period of at least about 2 years.

7. The method of claim 1, wherein the subject exhibits a reduction in triglyceride levels of at least about 5%.

8. The method of claim 1, wherein the subject exhibits a reduction in triglyceride levels of at least about 10%.

9. The method of claim 1, wherein the subject exhibits a reduction in triglyceride levels of at least about 15%.

10. The method of claim 1, wherein the subject exhibits a reduction in triglyceride levels of at least about 20%.
Description



CROSS-REFERENCE TO RELATED APPLICATION(S)

[0001] This application is a continuation of U.S. patent application Ser. No. 17/027,069 filed Sep. 21, 2020, which is a continuation of U.S. patent application Ser. No. 16/709,492 filed Dec. 10, 2019, which is a continuation of U.S. patent application Ser. No. 16/179,763 filed Nov. 2, 2018, which is a continuation of U.S. patent application Ser. No. 15/273,430 filed on Sep. 22, 2016 (now U.S. Pat. No. 10,220,013), which is a continuation of U.S. patent application Ser. No. 14/704,329 filed on May 5, 2015 (now U.S. Pat. No. 9,855,237), which is a continuation of U.S. patent application Ser. No. 14/175,602 filed Feb. 7, 2014 (now U.S. Pat. No. 9,056,088), which is a continuation of U.S. patent application Ser. No. 13/898,447 filed on May 20, 2013 (now U.S. Pat. No. 8,691,871), which is a continuation of U.S. patent application Ser. No. 13/540,319 filed on Jul. 2, 2012 (now U.S. Pat. No. 8,618,166), which is a continuation of U.S. patent application Ser. No. 13/417,899 filed on Mar. 12, 2012 (now U.S. Pat. No. 8,563,608), which is a continuation of U.S. patent application Ser. No. 13/266,085 filed on Jan. 30, 2012, which is a National Stage Entry of International Patent Application No. PCT/US10/32948 filed on Apr. 29, 2010, which claims priority from U.S. Provisional Patent Application No. 61/173,759 filed on Apr. 29, 2009, the entirety of each of which are incorporated herein by reference and relied upon.

BACKGROUND

[0002] Cardiovascular disease is one of the leading causes of death in the United States and most European countries. It is estimated that over 70 million people in the United States alone suffer from a cardiovascular disease or disorder including but not limited to high blood pressure, coronary heart disease, dyslipidemia, congestive heart failure and stroke.

SUMMARY

[0003] In one embodiment, the present invention provides a pharmaceutical composition comprising EPA and optionally one or more additional cardiovascular agents. In another embodiment, the EPA comprises eicosapentaenoic acid ethyl ester. In another embodiment, the composition contains substantially no amount of docosahexaenoic acid or derivative thereof (e.g. ethyl-DHA), if any.

[0004] In other embodiments, the present invention provides methods of treating and/or preventing a cardiovascular-related disease comprising administering to a subject in need thereof a pharmaceutical composition or composition(s) comprising EPA and optionally one or more additional cardiovascular agents.

[0005] In any of the foregoing embodiments, the EPA and additional cardiovascular agent(s) can be co-formulated as a single dosage unit or can be formulated as two to a plurality of dosage units for coordinated, combination or concomitant administration.

[0006] These and other embodiments of the present invention will be disclosed in further detail herein below.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board








Financial Market Data provided by
.
Loading...